Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice.

Abstract

Tadalafil, a selective phosphodiesterase type 5 inhibitor, is a long-acting oral agent for the treatment of erectile dysfunction of multiple etiologies. Although generalized tonic-clonic seizures were reported in a healthy man after taking tadalafil, the influence of tadalafil on seizure susceptibility has not been studied so far. Therefore, the aim of the present study was to investigate the effect of tadalafil on seizure threshold as well as on the activity of some first- and second-generation antiepileptic drugs in three acute seizure tests in mice. The obtained results showed that tadalafil, at the highest dose tested (20 mg/kg), significantly decreased the threshold for the first myoclonic twitch in the intravenous pentylenetetrazole (i.v. PTZ) seizure test. It did not affect the threshold for generalized clonic seizure and forelimb tonus in the i.v. PTZ, for tonic hindlimb extension in the maximal electroshock seizure threshold test, and for psychomotor seizure in the 6-Hz-induced seizure threshold test. Tadalafil did not alter the anticonvulsant activity of any of the studied antiepileptic drugs in electrically induced seizure tests. Interestingly, tadalafil potentiated the anticonvulsant activity of clonazepam and decreased the anticonvulsant activity of oxcarbazepine in the i.v. PTZ test. These interactions were pharmacodynamic in nature, as tadalafil did not alter clonazepam and oxcarbazepine concentrations both in serum and brain tissue. Furthermore, neither tadalafil alone nor its combinations with the studied antiepileptic drugs produced any significant impairment of motor coordination (assessed in the chimney test), muscular strength (investigated in the grip-strength test), and long-term memory (assessed in the passive avoidance task). In conclusion, tadalafil may increase the risk of myoclonic seizure and decrease the anticonvulsant efficacy of oxcarbazepine. Further studies are warranted to evaluate the safety of tadalafil usage in patients with epilepsy.

• Authors: Katarzyna Socała, Dorota Nieoczym, Mateusz Pieróg, Elżbieta Wyska, Małgorzata Szafarz, Urszula Doboszewska, Piotr Wlaź
• Journal: Neurotoxicity research (Neurotox Res) Vol. 34 Issue 3 Pg. 333-346 (Oct 2018) ISSN: 1476-3524 [Electronic] United States
• PMID: 29427285 (Publication Type: Journal Article)

Chemical References

• Anticonvulsants
• Convulsants
• Tadalafil
• Pentylenetetrazole

Topics

• Animals
• Anticonvulsants (metabolism, pharmacokinetics, therapeutic use)
• Avoidance Learning (drug effects)
• Brain (drug effects, metabolism)
• Convulsants (toxicity)
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Electroshock (adverse effects)
• Male
• Mice
• Movement Disorders (drug therapy, etiology)
• Muscle Strength (drug effects)
• Pentylenetetrazole (toxicity)
• Seizures (complications, drug therapy, etiology, metabolism)
• Sensory Thresholds (drug effects)
• Tadalafil (metabolism, pharmacokinetics, therapeutic use)
• Time Factors